– Funds will be used to establish clinical proof of concept for Artiva’s CAR-NK and universal NK cell therapies
– Artiva has exclusive access to a proprietary large-scale NK cell manufacturing platform and infrastructure
– First clinical study planned for later this year followed by two additional clinical programs
June 26, 2020 12:00 AM Eastern Daylight Time
SAN DIEGO–(BUSINESS WIRE)–Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies, announced today the launch of the company with the close of a $78 million Series A financing. The financing was co-led by 5AM Ventures, venBio Partners, and RA Capital Management, and joined by Medivate Partners and seed investors and strategic partners GC LabCell (Green Cross LabCell Corporation) (KRX: 144510) and GC (Green Cross Holdings Corporation) (KRX: 005250). Artiva will use the proceeds of this financing to develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies.
